Myriad Genetics
MYGN
MYGN
220 hedge funds and large institutions have $1.27B invested in Myriad Genetics in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 91 increasing their positions, 74 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
44% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 57
49% less capital invested
Capital invested by funds: $2.48B → $1.27B (-$1.22B)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
220
Holding in Top 10
–
Calls
$4.1M
Puts
$284K
Top Buyers
| 1 | +$53.4M | |
| 2 | +$15.2M | |
| 3 | +$12.9M | |
| 4 |
D.E. Shaw & Co
New York
|
+$12.3M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$9.09M |
Top Sellers
| 1 | -$60M | |
| 2 | -$15.7M | |
| 3 | -$15.3M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.1M |